GINELA LEININGER: Open Payments
NPI 1962079343 · MOBILE, AL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,942 in 80 payments from 30 companies in 2025. Trend: 2023 $1,784 · 2024 $1,547 · 2025 $1,942
Food & beverage: $1,680Education: $262
| Company | Payments | Amount |
|---|---|---|
| Novartis Pharmaceuticals Corporation | 14 | $263 |
| Astellas Pharma US Inc | 4 | $193 |
| Janssen Biotech, Inc. | 6 | $184 |
| Merck Sharp & Dohme LLC | 7 | $156 |
| Celgene Corporation | 5 | $128 |
| AstraZeneca Pharmaceuticals LP | 5 | $109 |
| SEAGEN INC. | 1 | $93 |
| Incyte Corporation | 4 | $92 |
| Exelixis Inc. | 4 | $76 |
| Daiichi Sankyo Inc. | 3 | $69 |
Products named: KISQALI, KEYTRUDA, RYBREVANT, REBLOZYL, IMFINZI, CABOMETYX, OPDIVO, BRUKINSA.
Industry payments across AL — which companies pay providers there.
